← Back to Clinical Trials
Recruiting Phase 2, Phase 3 NCT04273607

Anticoagulation-free VV ECMO for Acute Respiratory Failure

Trial Parameters

Condition Extracorporeal Membrane Oxygenation Complication
Sponsor Damian Ratano
Study Type INTERVENTIONAL
Phase Phase 2, Phase 3
Enrollment 40
Sex ALL
Min Age 18 Years
Max Age N/A
Start Date 2022-09-01
Completion 2026-12-31
Interventions
Subcutaneous Heparin

Brief Summary

Currently international experts recommend therapeutic anticoagulation for veno-venous extracorporeal membrane oxygenation (VV-ECMO). Reports and case series suggest that the absence of therapeutic anticoagulation is safe for VV-ECMO. No randomized control trials have assessed this. The aim of this pilot study is to assess safety and feasibility of an "anticoagulation-free strategy" for veno-venous ECMO (VV-ECMO) in Acute respiratory distress syndrome (ARDS).

Eligibility Criteria

Inclusion Criteria: * Adult patient with ARDS on VV-ECMO Exclusion Criteria: * Contraindication to anticoagulation with UFH (known heparin-induced thrombocytopenia, active hemorrhage, any surgery precluding the use of anticoagulation), * Indication for therapeutic anticoagulation (pulmonary embolism or deep vein thrombosis, chronic anticoagulation therapy before ECMO insertion) * Low-flow (\<2 liters/min) VV-ECMO (ECCO2R)

Related Trials